EuChemS is pleased to announce that Magnus J. Johansson, Senior Principal Scientist in Early CVRM Medicinal Chemistry at AstraZeneca Gothenburg, has been selected as the 2024 EuChemS Industry Innovation Awardee.
The EuChemS Industry Innovation Award recognises outstanding achievements by researchers or teams working in industrial chemistry, including joint collaborations with academia and research institutes. Magnus Johansson is honoured for his exceptional leadership in precision catalysis and sustainable medicinal chemistry, where he has embedded green-chemistry principles—such as PMI reduction, solvent optimisation, and life-cycle assessment, into modern drug-discovery workflows. His scientific contributions span transition-metal catalysis, C–H activation, photoredox chemistry, biocatalysis, and predictive approaches to late-stage diversification, significantly accelerating the path from molecular idea to candidate drug.
Magnus Johansson studied in Sweden (MSc, University of Gothenburg; PhD, Chalmers University of Technology) and conducted research at both UC Berkeley and Harvard University. At AstraZeneca, he plays a leading role in shaping global synthesis strategy and actively mentors PhD students and postdoctoral researchers. He also serves as Docent at Stockholm University and collaborates widely with academic partners in Sweden and internationally. Beyond his industrial work, he contributes to the broader chemical community through his involvement on the boards of SAFECHEM and the Swedish Chemical Society’s Organic Chemistry Division.
EuChemS warmly congratulates Magnus J. Johansson on receiving the 2024 Industry Innovation Award and thanks him for advancing innovative, sustainable, and high-impact chemistry within the pharmaceutical sector.
